• Karin Jordan, Franziska Jahn, Berit Jordan, Thomas Kegel, Carsten Müller-Tidow, and Jörn Rüssel.
• Department of Hematology/Oncology, University of Halle, Ernst-Grube-Str. 40, Halle 06120, Germany. Electronic address: karin.jordan@uk-halle.de.
• Crit. Rev. Oncol. Hematol. 2015 Jun 1;94(3):279-90.

AbstractTrabectedin is an approved antineoplastic agent for the treatment of adult patients with advanced soft tissue sarcomas or in combination with pegylated liposomal doxorubicin (PLD) in patients with relapsed platinum sensitive ovarian cancer. The mechanism of action is still not fully understood but many typical side effects seen with other chemotherapy drugs are less common, mild or unreported. Although this apparent favorable safety profile suggests a well-tolerated and manageable therapeutic option in the palliative care setting, trabectedin does have specific adverse side effects which can be hazardous for individual patients. The most commonly observed toxicities with trabectedin include neutropenia, nausea, vomiting, and increases in liver transaminases, anemia, fatigue, thrombocytopenia, anorexia and diarrhea. However, for most patients the appropriate use of supportive care strategies can reduce or overcome these side effects. We present a concise review of the safety data of trabectedin with the corresponding overview of the supportive care strategies.Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

29 keywords...

hide…